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Diet-induced metabolic endotoxemia is an important factor in the development of many
chronic diseases in animals and man. The gut epithelium is an efficient barrier that
prevents the absorption of liposaccharide (LPS). Structural changes to the intestinal
epithelium in response to dietary alterations allow LPS to enter the bloodstream, resulting
in an increase in the plasma levels of LPS (termed metabolic endotoxemia). LPS activates
Toll-like receptor-4 (TLR4) leading to the production of numerous pro-inflammatory
cytokines and, hence, low-grade systemic inflammation. Thus, metabolic endotoxemia
can lead to several chronic inflammatory conditions. Obesity, diabetes, and non-alcoholic
fatty liver disease (NAFLD) can also cause an increase in gut permeability and potential
pharmacological and dietary interventions could be used to reduce the chronic low-grade
inflammation associated with endotoxemia.
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gut permeabilityINTRODUCTION
Cani and colleagues (1) first defined metabolic endotoxemia as a diet-induced, 2–3-fold increase in
plasma LPS levels associated with low-grade inflammation, ultimately leading to the development of
cardiometabolic diseases. The serum levels of LPS seen after a 4-week exposure to high-fat diet
(HFD) were similar to that of mice continuously infused with LPS for 4 weeks to induce metabolic
endotoxemia (1). It should, however, be noted that the levels of LPS observed after the above diet
(and, indeed, in other models of metabolic endotoxemia) are 10–15 times lower compared to those
seen in animals or man with sepsis (1). Inflammation is a normal process of the host defense.
However, an unresolved (chronic) inflammatory response leads to low-grade, systemic
inflammation (2). Indeed, metabolic endotoxemia causes a state of low-grade inflammation,
which is a pathological feature of a range of chronic conditions including type 2 diabetes
mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, and
atherosclerosis (2).org January 2021 | Volume 11 | Article 5941501
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ENDOTOXEMIA
LPS
The term “lipopolysaccharide” was first introduced when it
became apparent that endotoxin contains both carbohydrates
and lipids (3). Endotoxins are complexes made up of LPS that
form the major component of the outer wall of Gram-negative
bacteria, while exotoxins are defined as those toxins that are
actively secreted by bacteria with a conserved lipid A “endotoxic”
component (4, 5). LPS is composed of three parts: Lipid A (fatty
acid and hydrophobic tail); the core divided into the inner and
outer core (oligosaccharide containing sugar residues) and the O
side chain (repeating sugar residues) (Figure 1) (6). LPS is a
potent activator of the inflammatory response and is a crucial
pathogen-associated molecular patterns (PAMPs) in Gram-
negative bacteria, consequently small amounts of LPS present
in the blood due to a bacterial infection is sufficient enough to
elicit an inflammatory response through the interaction with
Toll-like receptors (TLRs) (7). Hence, LPS is responsible for
pathophysiologic symptoms which is characteristic of infection
(8, 9). The ability of LPS to evoke signaling events and trigger the
release of cytokines from macrophages (and, indeed of Kupffer
cells in the liver) is dependent on the type of lipid A component
within the LPS structure.
Toll-Like Receptors
TLRs are single domain transmembrane plasma bound receptors
that belong to the pattern recognition receptors (PRRs) family as
well as NOD-like receptors (NLRs) and mannose. They are
important receptors in the innate immune system, as they are
able to detect the presence of microbial infections (10). TLRs
are expressed by immune cells such as macrophages, dendritic
cells, and non-immune cells, recognizing a variety of stimuli,
including conserved motifs of microbes known as PAMPsFrontiers in Immunology | www.frontiersin.org 2derived from various microbes such as LPS, lipopeptides, viral
double-stranded RNA, bacterial DNA, and danger-associated
molecular pattern molecules (DAMPs) derived from damaged
cells, such as heat shock proteins to help initiate and promote the
immune response (11). Each TLR recognizes specific microbial
components derived from pathogens (Table 1) and upon the
recognition of PAMPs, TLRs initiate the proinflammatory
signaling pathway via the recruitment of specific adaptor
molecules and the activation of transcription factors, nuclear
factor-kB (NF-kB), and interferon-regulatory factors (IRFs)
resulting in an immune response by producing inflammatory
cytokines, type I interferon (IFN) and other mediators. Pro-
inflammatory cytokines and the activation of microbicidal
responses is required to eliminate infection, however
overactivation of PRRs can cause systemic inflammatory
responses (15).
The Toll receptor was first discovered for its role in the
embryonic development of fruit-flyDrosophila melanogaster, as a
mutation in the Toll gene caused abnormal development in the
embryos compared to wild-type flies and they were more
susceptible to fungal infection. These mutated flies were
termed Toll, the German word for “wow” (16–18). Ten TLRs
members have been identified in humans (TLR1–TLR10) and 12
in mice (TLR1–TLR9, TLR11–TLR13). TLRs can be divided into
two subpopulations in terms of their cellular localization found
either on the outer membrane (TLR1, 2, 4, 5, 6, 10) capable of
recognizing microbial membrane components such as
lipoprotein, protein, and lipids or found in intracellular vesicles
such as the endosomal, lysosomal membranes, or the
endoplasmic reticulum (TLR3, 7, 9) that target viruses that
enter via endocytosis (19, 20). TLRs are able to recognize their
respective PAMPs, as each TLR is composed of an ectodomain
with leucine-rich repeats (LRRs) that adopts a horseshoe shaped
structure connected with the cytosolic carboxy-terminal domain,
the cytoplasmic Toll/IL-IR (TIR) domain and a transmembraneFIGURE 1 | The Structure of LPS. LPS is made up of three parts: Lipid A, core, and the O-polysaccharide chain. Covalently attached to lipid A is the core part of
the molecule, divided into the inner and outer core. The inner core is next to the lipid A section, which contains sugars such as L-glycerol-D-manno heptose (Hep)
and 3-deoxy-D-manno-octulosonic acid (Kdo). The outer core contains common sugars such as hexosamines and hexoses (Hex). Attached to the outer core are
repeating subunits of oligosaccharides, referred to as the O-chain (3). Adapted from Erridge et al. (3).January 2021 | Volume 11 | Article 594150
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pathway (15). The LRR motif is responsible for the recognition of
their respective pathogen and the cytosolic TIR domain is
necessary for the interaction with adaptor proteins, including
myeloid differentiation primary response gene 88 (MyD88), TIR-
containing adaptor protein (TIRAP), TRIF-related adaptor
molecule (TRAM), and Toll/interleukin-1 receptor domain-
containing adapter inducing interferon-b (TRIF) and hence
necessary for the initiation of the downstream signaling
transduction (21).
Toll-Like Receptor 4 Signaling
TLR4 recognizes bacterial LPS, binding of which leads to cellular
activation, causing the release of proinflammatory cytokines.
This strategy of recognition is the first line of defense against
bacterial infections and LPS is the most powerful immunostimulant
known to date. The lipid A moiety is the main PAMP within LPS
and if excessive signaling occurs through TLR4, this can induce
systemic inflammation, a cytokine-storm, and ultimately
sepsis (22).
On the cell surface, the first protein involved in the
recognition of LPS is the LPS-binding protein (LBP). LBP is
present as a soluble protein or a plasma membrane protein in the
bloodstream, it recognizes and forms a complex with the lipid A
part of LPS in the plasma allowing LPS to dock at the LPS
receptor complex resulting in the LPS-LBP complex. LBP allows
LPS to interact with CD14 on the cel l surface , a
glycosylphoshatidylinositol-anchored protein containing LRRs,
binds LBP and transfers LPS-LBP to the co-receptor of TLR4,Frontiers in Immunology | www.frontiersin.org 3myeloid differentiation protein-2 (MD-2) and TLRs are able to
detect LPS with the help of this accessory protein, MD-2, a
secreted glycoprotein, which non-covalently associates with
TLR4 and acts as a binding site for LPS (4). Once LPS binds to
the TLR-CD14-MD-2 complex and is recognized, TLR4 is
activated and undergoes oligomerization, allowing the
recruitment of the downstream adaptors through the
interaction with TIR domains due to the conformational
change of the extracellular domain allowing the dimerization
of the cytoplasmic TIR domain. The LPS/TLR4 mediated
response triggers two distinct signaling pathways: the MyD88-
dependent pathway which tends to occur earlier and is utilized
by all TLRs, except TLR3. This involves the recruitment of
TIRAP at the cell membrane followed by the recruitment of
MyD88 and the MyD88-independent pathway which occurs
during the late phase response which involves the trafficking of
TLR4 to the endosome and the recruitment of TRAM and TRIF
(22, 23).
MyD88-Dependent Pathway
MyD88 belongs to the family of cytosolic TIR domain-
containing adaptor molecules (24). Upon stimulation with a
ligand, the MyD88-dependent pathway involves the recruitment
and activation of IL-1 receptor-associated kinase 4 (IRAK-4),
linking TLRs to IL-1Rs. The death domain recognizes the
conformational change of the TIR domain of TLRs and binds
to the new conformation allowing the transfer of signaling by the
interaction of the death domain of the MyD88 with IRAK
kinases family membranes, known as Myddosome. There are
four IRAKs (IRAK-1, 2, 3, 4) that contain an N-terminal death
domain and a central serine/threonine-kinases domain. During
the Myddosome formation, IRAK4 activates IRAK1 and
undergoes autophosphorylation, allowing the association with
the adaptor protein, TNF-a receptor associated factor 6
(TRAF6), which is critical for the activation of this pathway.
The activation of IRAK1 allows the binding to the TRAF domain
of TRAF6. The IRAK1/TRAF6 complex then dissociates from
the receptor and associates with TAK1 and TAK1-binding
proteins (TAB1 and TAB2). TAK1 is a member of the mitogen
activated protein kinase kinase kinase (MAPKKK) family and
forms a complex with the regulatory subunits (TAB1 and TAB2)
that interact with K63-linked polyubiquitin chains generated by
TRAF6, along with ubiquitin-conjugating enzyme, ubiquitin-
conjugating enzyme E32 variant 1 isoform A (UBC13) and
UEV1A to drive the activation of the transforming growth
factor-b-activated kinase (TAK1). The TRAF6, TAK1, TAB1,
and TAB2 complex then moves to the cytoplasm and forms a
complex with UBC13. TAK1 then activates the IKK complex, the
catalytic subunits IKKa and IKKb and the regulatory subunit
NEMO (known as IKKg). Through ubiquitin chains TAK1
phosphorylates IKKb. This leads to the degradation of IKb and
the release of free NF-kB (p50/p65). The IKK complex
phosphorylates the NF-kB inhibitory protein, IkBa, which in
turn allows the translocation of NF-kB to the nucleus, initiating
the transcription of proinflammatory genes including IL-18, IL-
6, IL-1a, and IL-1b (Figure 2) (15).TABLE 1 | Examples of pattern recognition receptors (PRRs) and their specific
pathogen-associated molecular patters (PAMPs).
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TLR11 Parasites Profilin-like moleculesTable adapted from Marshall et al. (12), Doughty (13), and Kawai et al. (14).January 2021 | Volume 11 | Article 594150
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The MyD88-independent pathway is also known as the TRIF
dependent pathway. This pathway is initiated by TRAM and
TRIF. This pathway is specific to a few TLRs and once stimulated
the adapter protein, TRIF is important for recruiting TNF
receptor associated factor 3 (TRAF3). TRAF3 recruits the IKK-
related kinases, TRAF family member-associated NF-kB
activator-binding kinase (TBK1) and IKKe, leading to the
phosphorylation of interferon regulatory factor 3 (IRF3), which
forms a dimer and results in the translocation into the nucleus,
resulting in the activation of the expression of IFN inducible
genes and inflammatory mediators (Figure 2) (15, 25).INTESTINAL CHANGE
Components of the Intestinal Epithelial
The small and large intestines form the major part of the
gastrointestinal tract that follows the stomach. The smallFrontiers in Immunology | www.frontiersin.org 4intestine consists of three divisions: the duodenum, the
jejunum, and the ileum. The duodenum is the first and
shortest part of the small intestine involved in chemical
digestion. The jejunum is the middle part of the small intestine
where nutrients are absorbed into the blood and the ileum is
between the jejunum and the cecum. The mucous membrane
lining the jejunum is covered with villi and the ileum is where the
remaining nutrients are absorbed, the inner surface is also
covered with villi. The small intestine consists of four tissue
layers: mucosa, submucosa, muscularis, and the serosa. The
intestinal epithelial are one-cell-thick, lining of the surface of
the intestinal epithelium that form a barrier between the mucosal
tissue and the lumen to protect humans (and animals) against
invading microorganisms. Each epithelium has a finger-like
projection called villi, brush border, crypt, and basolateral
plasma membrane structure (26, 27). Each individual villus
contains a rich capillary network and between the villi are
intestinal glands (crypts of Lieberkuhn) and each crypt
contains approximately 250 cells with the size and organizationFIGURE 2 | TLR4 signaling via MyD88-dependent and independent pathway to activate NFkB related target genes: Upon stimulation of myeloid differentiation
primary response protein 88 (MyD88) dependent pathway involves the activation of MyD88 which recruits IL-1 receptor-associated kinase-4 (IRAK-4). IRAK-4
phosphorylates IRAK-1 and allows tumor necrosis factor receptor associated factor 6 (TRAF6) to associate with IRAK1. IRAK1/TRAF6 then activates TAK1, TAB1,
and TAB2. The TRAF6, TAK1, TAB1, and TAB2 forms a larger complex with ubiquitin-conjugating enzyme E32 variant 1 isoform A (Ubc13) and Uev1A which
activates TAK1. Polyubiquitin chain is then removed by A20 and conserved cylindromatosis (CYLD). Activated TAK1 phosphorylates the IKK complex (IKKa. IKKb
and IKKg) ultimately resulting in the translocation of nuclear factor-kB (NF-kB) into the nucleus, resulting in the transcription of proinflammatory cytokines. MyD88
independent pathway involves TIR-domain-containing adapter-inducing interferon-b (TRIF) leading to the activation of TNF receptor associated factor 3 (TRAF3) and
the translocation of interferon regulatory factor 3 (IRF3) to the nucleus leading to IFNB gene transcription. Image made using BioRender.January 2021 | Volume 11 | Article 594150
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the base of the crypt give rise to four cells in the intestinal
epithelial including enterocytes, enteroendocrine cells, goblet
cells, and Paneth cells which are only found in the small
intestine, these differentiated cells are continuously being
supplied and are pushed upward towards the mouth of the
crypt where they move to the distal end of a villus and are
shed. Hence, it is the most rapid self-renewing tissue of adult
mammals (27). The enterocytes are the most abundant cells and
predominantly line the lumen of the small intestine that are
important for digestion and absorption of nutrients. The
enterocytes are assisted by the mucus secreting goblet cells
found in large numbers on villi important for the synthesis
and secretion of mucin. The mucus layer is the first line of
defense, as it is a chemical barrier, consisting of digestive
secretions, immune molecules, antimicrobial peptides (AMPs),
and cytokines. This layer is crucial to limit the contact between
the microbiome and epithelial cells (29). The gastrointestinal
hormone secreting enteroendocrine cells are important for
hormonal regulation and Paneth cells are important for the
immunological function, secreting antimicrobial peptides to
promote the exclusion of bacteria from the epithelial surface.
Paneth cells are found at the base of the small intestine crypts,
hence protecting the stem cells (30). Other components of the
intestinal epithelial include the luminal release of secretory IgA
and the microfold cells (M cells), important for the delivery of
antigens to immune cells. Tuft cells which secrete endorphins
and enzymes such as prostaglandins. Immune cells are also
present, including T cells, B cells, dendritic cells, and
macrophages that help to maintain intestinal homeostasis
(Figure 3) (29).
Cell Junctional Protein Complexes and a
Leaky Intestinal Barrier
An important component of the intestinal barrier is the ability of
the single layer of intestinal epithelial cells to attach to each other
by forming intracellular junctional complexes, composed of tight
junctions, adherens junctions, desmosomes, and gap junctions.
Tight junctions are critical for maintaining the physical barrier
integrity by selectively limiting the diffusion of small molecules,
water, and ions as well as protecting the body against infection
and inflammation. The integrity of tight junctions is regulated by
the arrangement of actin together with the interaction between
the peripheral and integral transmembrane proteins such as
occludins, claudins, and junctional adhesion molecule (JAM)
to form a tight seal between adjacent epithelial cells and are at the
apical part of the junctional complex. The complex is
strengthened by cytoplasmic scaffolding and adapter proteins,
such as ZO-1, -2, and -3 (Zona occluden) (Figure 4) (31). Tight
junctions act as a fluid barrier preventing the diffusion of solutes,
ions, and other molecules across between the two cells. Thus,
abnormalities in tight junctions are associated with metabolic
and inflammatory diseases, as well as cancer, since tight
junctions can be affected by pathogens and commensal bacteria
(32–35). Below the tight junctions are the adherens junctions
important for cell to cell signaling by joining the actin filamentsFrontiers in Immunology | www.frontiersin.org 5of neighboring epithelial cells and supporting epithelial stability
(36). Adherens junctions consist of E-cadherin and nectin
transmembrane spanning proteins and these proteins are
anchored by intracellular components of the catenin family, b-
catenin which binds a-catenin, which in turn bind to other
proteins such as afadin in a protein complex with actin filaments,
regulating the organization of the actin cytoskeleton (31, 37, 38).
The extracellular domain of the nectin transmembrane protein
bind to those nectin on neighboring epithelial cells, while the
cytoplasmic tail binds afadin (Figure 4). At the basolateral end of
the epithelial cells are desmosomes and these cannot prevent the
movement of solutes between cells as they are not continuous,
instead they mainly provide mechanical strength by joining the
intermediate filaments of neighboring epithelial cells involved in
cell-cell adhesion (35, 39). The cytoplasmic side of each plasma
membrane has a plaque belonging to the plakoglobin (Pg) and
plakophilins or the plakin family (desmoplakin), and these are
joined to cells by linker proteins which includes the cadherin
proteins, desmoglein, and desmocollin in the extracellular space
(40). The intermediate keratin filaments anchor the desmosomes
together at the opposite sides of the cells by attaching to the
cytoplasmic protein plaque (Figure 4). Gap junctions are made
up of connexins that form a channel to allow the transport of
small molecules between neighbouring cells and play a
regulatory role in cell growth and differentiation (Figure 4) (41).
Regulation of Tight Junctions
The assembly and maintenance of tight junctions are regulated by
signaling pathways, such as protein kinases C (PKC) and myosin
light chain kinases (MLCK). ZO-1 and occludin interact with PKC
and phosphorylation of tight junction proteins by PKC is associated
with tight junction regulation. As the C-terminus of occludin
interacts with ZO-1 and is phosphorylated on the serine/
threonine residues (42). Once stimulated, the tight junctions open
leading to the paracellular movement of ions, solutes, and peptides
across the intestinal epithelium (26). Proinflammatory cytokines
such as TNF-a and IFNg also cause an increase in tight junction
permeability, since TNF-a activates the NF-kB pathway and
decreases the level of ZO-1 protein with IFNg also causing a
reduction in ZO-1, both suppressing the tight junction barrier
function (43, 44). TNF-a stimulation of NF-kB signal
transduction pathway regulates MLCK, increased levels of MLCK
leads to an increase in tight junction permeability. This allows LPS
to leak into the bloodstream leading to low-grade inflammation,
including steatosis and insulin resistance. As LPS can interact with
immune cells and adipocytes, this then drives a potentially chronic,
systemic inflammation. Inhibition of the activation of NF-kB by
pharmacologic inhibitors cause the inhibition of the activation of
MLCK and leads to a decrease in tight junction permeability (45).
The small intestine is important for the absorption of
nutrients and, hence, has a larger surface area than the large
intestine to allow the digestion and absorption of nutrients.
However, the large intestine has a higher number of bacteria
(1011) compared to the small intestine (108) (46). Hence,
although the small intestine is the easiest for the translocation
of LPS it does not have the highest bacterial concentration whichJanuary 2021 | Volume 11 | Article 594150
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main source of the LPS in metabolic endotoxemia. The number
of gut bacteria is approximately 10-times that of all the cells
present in the human body (47). LPS alters the intestinal
epithelial tight junction protein assembly (ZO-1 and occludins)
of the intestinal epithelium contributing to a “leaky gut,”
allowing the translocation of LPS from the lumen of the
digestive tract into the bloodstream, resulting in endotoxemia
and the overproduction of pro-inflammatory cytokines (Figure
5). Tight junction permeability is mediated by TLR-4 activation
by MyD88 on the membrane of the epithelium, allowing the
intestinal epithelium to respond to inflammation by bacteria and
proinflammatory cytokines, ultimately leading to intestinal
inflammation (26). Many studies have investigated the
intestinal bacteria as a main source of LPS, ultimately causing
metabolic endotoxemia (after translocation to the luminal side)
(48–50). While the cytokine storm triggered by the release of
large amounts of LPS (sepsis) can lead to shock and potentially
organ failure, the long term effects of low-grade endotoxemia are
associated with an increased risk of cardiovascular disease and
T2DM driven by metainflammation (51, 52).Frontiers in Immunology | www.frontiersin.org 6Metabolic and inflammatory disorders including obesity, non-
alcoholic steatohepatitis (NASH), and inflammatory bowel
disease (IBD) are linked to a defect in tight junction barrier of
the intestinal epithelial. Therefore, maintaining tight junction
integrity is a possible strategy to treat these diseases. HFD
induced metabolic disorders are associated with gut dysbiosis
in both animal and human studies have investigated the effect of
various HFD on the alterations of the microbiome within the
intestine (53, 54). HFD is also associated with alterations in the
intestinal barrier, which allow an increase in permeability and
hence, the translocation of LPS into the bloodstream activating
the TLR4 signaling pathway (49, 55).EVIDENCE OF METABOLIC
ENDOTOXEMIA IN HUMAN AND ANIMAL
STUDIES
Metabolic endotoxemia causes both local and systemic
inflammation, which contributes to many cardiometabolicFIGURE 3 | Components of the intestinal epithelial cells of the small intestine. The intestinal epithelium is composed of a signal layer of intestinal epithelial cells (IECs)
covered by a mucus layer continuously secreted by goblet cells to act as a first physical barrier against pathogenic bacteria. The outer mucus layer is colonized by
bacteria whereas the inner mucus is a bacteria-free loose layer. Paneth cell secrete antimicrobial peptides (AMPs) into the inner mucus and enteroendocrine cells
produce hormones where secretory IgA (sIgA) are also present to protect against commensal bacteria and contribute to the formation of a biochemical barrier. Stem
cells are located at the base of the crypt that give rise to four cells in the intestinal epithelial: enterocytes, enteroendocrine cells, goblet cells, and Paneth cells that
migrate upwards and move to the distal end of a villus where they are shed. Enteroendocrine cells produce hormones, goblet cells produce mucus, and Paneth cells
produce AMPs. Other cells include truft cells, macrophages, dendritic cells T-cells, B-cells, and M-cells in the Peyer’s patches of the intestine involved in transporting
antigens from the lumen to cells of the immune system. Image made using BioRender.January 2021 | Volume 11 | Article 594150
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evidence for metabolic endotoxemia in both human and
animal studies.
When comparing 559 overweight males and females with 500
volunteers of normal weight, LBP was elevated (assumed to be
secondary to endotoxemia). LBP is a marker of the acute phase
response, hence, serum LPS levels frequently correlate with
conditions associated with low-grade inflammation. Thus, it
is difficult to conclude with certainty whether a rise in LBP in
diseases associated with inflammation is secondary to the
systemic inflammation or due to endotoxemia (56).
Nevertheless, plasma LBP levels have been investigated in
many metabolic disorders, as LBP is synthesized in the liver
and initiates the recognition of LPS, delivering LPS to other
adaptor molecules to trigger the TLR4 signaling pathway and the
production of proinflammatory cytokines. Plasma LPS levels
were 76% higher in patients with T2DM when compared to
control participants. In obesity and T2DM, LPS also activates an
immune response in human adipose tissue. In patients with
T2DM, the activation of NF-kB results in the formation
of adipocytokines in adipose tissue. In T2DM, the functionFrontiers in Immunology | www.frontiersin.org 7of Kupffer cells is impaired, resulting in a reduction in
the clearance of LPS. Treatment of human abdominal
subcutaneous adipocytes with LPS resulted in a significant
increase in the secretion of the pro-inflammatory cytokines,
TNF-a and IL-6. In addition, the expression of TRAF6 and
MyD88 is increased in patients with T2DM. Inhibition of the
activation of NF-kB in human abdominal subcutaneous
adipocytes reduced the formation of IL-6. Taken together,
these findings suggest that T2DM is associated with
endotoxemia, which leads to the activation of abdominal,
subcutaneous adipocytes and a subsequent immune response
(57). In 192 individuals with atherosclerosis, the serum levels of
endotoxin were positively correlated with the waist to hip ratio,
waist circumference, serum insulin, triglycerides levels, and total
cholesterol. However, endotoxin was negatively correlated with
serum HDL-cholesterol (58). In children with NAFLD, the
serum endotoxin, TNF-a, IL-6, and PAI-1 levels were higher
suggesting that endotoxemia can contribute to the progression of
NAFLD (59). In human studies, a controlled-feeding study
showed within 24 h of initiating a high-fat/low fiber or low-fat/
high fiber diet there was a positive association betweenFIGURE 4 | Intestinal epithelial cell junctional proteins. Tight junctions are at the apical end of junctional complexes composed of three transmembrane proteins:
occludin claudins and junctional adhesion molecules (JAMs) that bind intracellular membrane proteins, zonula occludens (ZOs) which connects the transmembrane
tight junction to the actin skeleton. Below the tight junctions are adherens junctions composed of transmembrane proteins, E-cadherin and nectin linked to the
cytoskeleton by scaffolding proteins, catenin and afadin linked to actin filaments. Desmosomes are made up of the transmembrane liner glycoproteins, desmoglein
and democollin which are cadherin proteins linked to intermediate keratin filaments. Gap junctions form a tunnel for small molecules to pass between adjacent
epithelial cells. Image made using BioRender.January 2021 | Volume 11 | Article 594150
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between Firmicutes and Proteobacteria (60).
Metabolic syndrome is a group of conditions that occur
together, leading to an increased risk of cardiovascular risk
factors. Tissue factor (TF) in the circulation triggers the
procoagulant pathway of coagulation and in atherosclerotic
plaques they are expressed on peripheral blood monocytes
(PBMCs). Stimulation of PBMCs with LPS leads to the
induction of monocyte TF and an upregulation of LPS in
patients with metabolic syndrome (61). Therefore, suggesting
metabolic syndrome upregulation of monocyte TF is
significantly associated with low-grade inflammation.
Numerous studies have suggested a link between high fat-or
high-energy, high carbohydrate diets and endotoxemia. HFD can
cause changes to bacterial diversity, increased permeability and
integrity of gut wall membrane (62). A population-based study of
1,015 healthy men reported a link between energy intake and the
plasma levels of LPS, and a similar link was found in mice
challenged with a high fat-or high-energy, high carbohydrate diet
for 4 weeks (63). Many other studies have found a link between a
high fat-or high-energy, high carbohydrate diet and an increase
in LPS (64, 65) also an increase in the expression of TLR2 and
TLR4 (64). Mouse models have shown the importance of TLR4
and its signaling in diet-induced insulin resistance and
atherosclerosis (66). TLR4 knockout mice challenged with a
HFD develop less insulin resistance and have a better glucose
tolerance test than their wild-type litter mates (67, 68). TLR4-Frontiers in Immunology | www.frontiersin.org 8deficient mice also develop less atherosclerosis (69). Specifically,
atherosclerosis-prone ApoE−/−mice deficient in TLR4 or MyD88
have less atherosclerotic plaques associated with a reduction in
macrophage recruitment (70). An increase in serum LPS was also
observed using the limulus amebocyte lysate assay when
investigating the effect of nutritional intake in patients with
cardiometabolic diseases, supporting the role of bacterial
infections and the immune response in cardiometabolic
diseases (52). In 208 healthy male subjects over 4 weeks
consuming a high-fat or high-carbohydrate diet showed a link
between food intake and the levels of plasma LPS (63).
Many studies have looked into the mechanism(s) by which
HFD can cause the translocation of LPS: HFD causes an increase
in the gut permeability and/or changes in the composition of gut
microbiota, which in turn result in the formation of larger
amounts of LPS which then translocate into the bloodstream.
Feeding mice a HFD for 4 weeks resulted in an increase in serum
LPS (metabolic endotoxemia) due to changes in gut microbiota:
Specifically, HFD caused a reduction in the intestinal bacteria,
Bifidobacterium and Eubaterium spp (1).. This study triggered
the interest in HFD-induced dysbiosis and raised questions
about the importance of the intestinal microbiota in obesity
and related comorbidities. In another study, exposure of mice to
a HFD for 7 weeks caused an increase in body weight, blood
glucose, higher levels of hepatic triglycerides, and a reduction in
the ratio of Bacteroidetes to Firmicutes (71). In rats, a HFD for 16
weeks resulted in an increase in the intestinal permeability, aFIGURE 5 | Comparison between a healthy and “leaky gut.” A “leaky gut” affects the lining of the intestine and tight junctions are damaged in response to stress for
example, a high-fat diet, this allows the passage of LPS and other pathogens into the bloodstream, causing the activation of the immune system and inflammation.
Image made using BioRender.January 2021 | Volume 11 | Article 594150
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claudin-3, occludin, and junctional adhesion molecule-1) in the
small intestine and an increase in plasma TNF-a (72). Feeding
mice a HFD for 4 weeks caused an increase in the intestinal
permeability and a reduction in the tight junction gene
expression, suggesting that HFD has an effect on intestinal
function (55). Interestingly, genetically obese mice (ob/ob and
db/db) also have elevated levels of LPS and pro-inflammatory
cytokines IL-1b, INFg, and TNF-a (73). These findings support
the view that an increase in intestinal permeability drives
systemic endotoxemia. Other animal studies showed that
feeding mice a HFD for over 8 weeks resulted in an increase in
LBP. Mice lacking TLR4 or the co-receptor CD14 showed no
change in body weight (74).POTENTIAL PHARMACOLOGICAL
INTERVENTIONS
Multidrug-resistant Gram-negative bacteria is becoming an
increasing problem. Hence, new strategies are needed to
overcome this and protect patients. The activities of LPS are
mediated by the lipid-A residue of the molecule, containing the
molecular components which is important to determine the
endotoxic activity of LPS. Therefore, anti-endotoxin therapies
have been considered as potential treatment strategy. Antibodies
are effective for therapeutics due to their specificity. For example,
O-polysaccharide specific antibodies reduce the toxic effects of
LPS. In the 1960’s, more research was conducted regarding the
structure of LPS and it was made clear that the O-polysaccharide
part of LPS was immunodominant, as immunizing animals with
specific stereotypes of bacteria led to the induction of antibody
production directed against the specific O-polysaccharide (75).
Another possible intervention includes approaches to neutralize
the toxicity of the lipid A moiety of LPS, hence preventing the
interaction with host tissues such as polymyxins. Polymyxins are
antibiotics that combine a bactericidal activity with the ability of
neutralizing endotoxins (76). Due to the excessive use and
misuse of antibiotics, there is increasing antibiotic resistance
which is becoming a major problem. Antibiotic resistance places
an economic burden on the health care system and each year
about 700,000 people worldwide die from drug-resistant strains
(77). Therefore, antibiotic alternatives are needed to reduce the
number of deaths and to allow a reduction in antibiotic use.
Antimicrobial Peptides
Mechanism of Action of Antimicrobial Peptides
Even though AMPs are part of innate immunity, the mechanism
of action of killing microbes differs from those of phagocytes and
cytokines. AMPs are capable of killing bacteria by interacting with
bacterial cell wall or membranes (78). Most AMPs are induced in
response to cytokines or PAMPs and are synthesized shortly after
an infection to neutralize a range of microbes, while some are
constitutively expressed and are stored as inactive precursors in
granules within phagocytes at high concentrations and protectFrontiers in Immunology | www.frontiersin.org 9their hosts against many microorganisms as they are locally
released at sites of infection and inflammation (79). They have a
broad spectrum and can target organisms such as fungi, yeast,
viruses, and bacteria (Gram-positive and Gram-negative). AMPs
also prevent the formation of biofilms and they have anti-cancer
properties (80).
The mechanism by which AMPs bring about their
antimicrobial effects are not entirely understood but include
direct killing and immune modulation. These mechanisms are
dependent on several physicochemical properties of the AMP
such as secondary structure, charge, and amphipathic properties.
All biological membranes are composed of a fluid mosaic, made
up of phospholipids and proteins. Therefore, AMPs with ~50%
hydrophobic residues fold into a amphipathic confirmation and
with a net positive charge (+2 to +9) (81), allows the peptide to
interact with the negatively charged bacterial phospholipid head
groups on the inner leaflet of the membrane, disrupting the
bacterial cell membrane non-enzymatically and allowing the
translocation of the peptide into the bacterium to affect
internal targets (80).
Microbial membranes differ from animal cell membranes and
this allows AMPs to distinguish their target, as they are more
selective for bacterial membrane, since animal cell membranes
have zwitterionic rather than negatively charged phospholipids
and also contain cholesterol that helps to protect the membrane
from damage (81). Therefore, there is only a weak interaction
with the zwitterionic phospholipids of plant and mammalian
membranes. The electrostatic interaction of the peptide with the
negatively charged molecules on the bacterial membrane is a
strong interaction and this causes disruption, such as pore
formation in the bacterial membrane leading to the destruction
of the integrity of the membrane. It is this interaction that is the
main mechanism of action of AMPs for producing their
antimicrobial activity. Studies have looked at the correlation
between charge and the antimicrobial activity of AMPs, a charge
of +3 to +5 showed to improve the antimicrobial activity of the
AMP against both Gram-positive and Gram-negative bacteria.
However, increasing the charge to +6 or +7 caused a loss in the
antimicrobial activity, suggesting too strong of an interaction and
hence preventing the peptide from translocation (80). This
suggests the importance of charge in the mechanism of action
of AMPs.
In other cases, AMPs produce their antimicrobial activity by
entering the bacterium by translocation to inhibit intracellular
functions such as nucleic acid synthesis, protein synthesis, and
enzymatic activity. Both mechanisms of action of AMPs lead to
bacterial lysis (78). However, some peptides can cross the lipid
barrier without causing damage to the bacterial membrane, such
as by blocking the enzyme activity or inhibiting the synthesis of
proteins. For example, phospholipase A2 (PLA2) is secreted from
platelets and hydrolyses the bacterial membrane by enzymatic
digestion to kill the bacteria (78).
Some AMPs modulate host immunity by either activating or
recruiting immune cells of the adaptive immunity such as, T-
cells, macrophages and neutrophils or by effecting toll-like
receptor responses, thereby controlling inflammation and/orJanuary 2021 | Volume 11 | Article 594150
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37, has been shown to act as a chemoattractant, attracting
neutrophils, mast cells, monocytes, and T-cells. This is
achieved by LL-37 acting as a ligand of the formyl peptide
receptor-like 1 (FPRL1) and the Gi coupled receptor (83).
AMPs have also shown to have anticancer activity, as the
outer layer of cancer cells is often a negatively charged
phosphatidylserine (PS), hence enhancing the interaction with
AMPs (84). AMPs are also able to specifically target cancer cells,
as these overexpress of other negatively charged molecules, such
as O-glycosylated mucins and heparan sulphate (80).
The rising rate of multi-drug-resistant bacteria has led to
difficulty in treating patients that are critically ill due to the
misuse or excessive use of antibiotics. Hence, AMPs have become
a focus as new treatments of infections. Killing of bacteria by
antibiotics results in the release bacteria-derived wall fragments,
including LPS or lipoprotein (LP). This leads to the initiation of
the pro-inflammatory cascade potentially causing harm to
patients taking these anti-infective agents (85). Understanding
the importance of AMPs in the gut could lead to the discovery of
novel therapies for enteric infection, since antimicrobial peptides
not only scavenges the LPS that is released when they kill bacteria
but they also manage microbiome diversity (86).
Intestinal Antimicrobial Peptides
The human gut is colonized with trillions of microorganisms and
the small intestine is the main site for microbial colonization.
AMPs including C-type lectins and a-defensins, lysozymes, and
phospholipase A2 are secreted by Paneth cells, located at the
bottom of crypts of Lieberkuhn to protect against infections and
help to maintain the intestinal homeostasis (87). Intestinal AMPs
are capable of ingesting pathogens and play a role in maintaining
a healthy balance between the host and the number of
commensals (78).
Defensins
The largest group of AMPs, the defensins, are involved in
antiviral, antibacterial, immune, antifungal, and inflammatory
responses and are expressed in both vertebrates and
invertebrates. Defensins are an important part of the innate
immunity and have b-sheet structures and are cationic peptides
with antimicrobial properties. Humans have 17 defensins, all of
which consist of a b-sheet fold stabilized by three disulfide bonds
formed by six conserved cysteine residues and are classified into
three different subfamilies based on the location of the disulfide
bond: a, b, and q defensins (88, 89). The human a-defensins 1–4
(HD1–4) is also known as the human neutrophil peptides
(HNP1–3), stored in the granules of neutrophils and are found
in the airways. In particular, HBD-3 has shown to reduce LPS
induced TNF-a and IL-6 in both mouse and human
macrophages (90). Human b-defensins 1–4 (HBD 1–4) are
secreted predominately by epithelial cells and in humans there
are six enteric defensin a-defensins, DEFA1–6 (91). Human b-
defensin 5 and 6 (HD5 and 6) are both produced by Paneth cells
and five mouse b-defensins (mBDs) (88, 91).
Enteric a-defensins are an important component of the
mucosal innate immunity which was first discovered in PanethFrontiers in Immunology | www.frontiersin.org 10cells in mouse small intestine which are stored in secretory
granules as the inactive pro-peptide and a proteolytically
cleaved to allow for their antimicrobial activity (92). Paneth
cells contain a matrix metalloproteinase enzyme, matrilysin
(MMP-7), which is important for processing the active form of
the peptide (93). Whereas, HD-5 and HD-5 are processed by
trypsin following their release. The importance of MMP-7 was
shown in MMP-7 knockout mice, the MMP-7 deficient mice
only secreted the inactive precursor form of the propetide in their
Paneth cells (94). In the ileum of the small intestine, LPS causes
the activation of MMP-7 and MMP-7 knockout mice are
protected against LPS-induced leakage of the gut during
endotoxemia. Hence, MMP-7 knockout mice show less severe
inflammation in the gut with a reduction in the production of
TNF and IL-6 in the ileum (95). Patients with Crohn’s disease
have a decreased expression of a-defensins, suggesting that
AMPs reduce enteric inflammation and/or prevent the
development of inflammatory bowel disease (96).
Defensins could be a potential intervention used for the
treatment of endotoxemia, as they play a key role in the innate
immune system. Human defensins are naturally occurring, non-
toxic microbicides that protect the host from invading microbes
in the small intestine. Human beta defensin 1 (hBD1) has minor
antibiotic activity, however, reducing the disulfide bridges in
hBD1 increases the antimicrobial activity (97). hBD1 is secreted
as an oxidized form of the peptide, HD5OX, which has the widest
spectrum of antibacterial activity of the a-defensins. Thus,
HD5OX could be the most promising target against antibiotic
resistant pathogens. HD5OX causes changes to Escherichia coli
and other Gram-negative microbes. This morphological change
includes bleb formation and a study using E. coli expressing GFP
showed that treatment with HD5OX caused GFP emission in the
bleb (98).
Cathelicidin
All members of the cathelicidin family of peptides have a
conserved amino-terminal cathepsin L inhibitor domain
(cathelin) and play an essential role in host defense (99).
Cathelicidins have an a-helix structure with a highly conserved
N-terminal region and a C-terminal domain, which contains the
antimicrobial properties. Cathelicidin is produced by several cell
types such as keratinocytes, immune cells, urinary tract,
sebocytes, and bone-marrow-derived cells found within the
skin (100). The first mamalian, cathelicidin AMPs were
isolated from bovine neutrophils and named Bac5 and 7 (101).
Cathelicidins are one of the most diverse AMPs of vertebrates
and are found in many mammals including sheep, bovines,
horses, goat, and mice (80).
In addition to the antimicrobial properties of AMPs, LL-37/
hCAP18 is the only member of the cathelicidin family of AMPs
known in man and it regulates inflammatory and immune
responses. In humans, cathelicidin antimicrobial peptide
(CAMP) encodes for LL-37, which has also been named,
hCAP18 which is the precursor protein. LL-37 contains a
signal peptide, N-terminal domain and a C-terminal domain.
The C-terminal domain has a variety of activities and is called
LL-37, as the protein releases LL-37 from its C-terminal domain.January 2021 | Volume 11 | Article 594150
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amphipathic. LL-37 is found throughout the body, but is
mainly produced in mast cells, neutrophils and monocytes
(102). LL-37 has bactericidal properties and are capable of
neutralizing pathogen factors, such as lipopolysaccharides
(LPS) or lipoprotein (LP), both of which are released during
infection/injury. Through electrostatic interactions, LL-37 can
bind to bacterial membranes and cause membrane disruption
and hence peptide insertion (78). A study showed that LL-37
treated with E. coli demonstrated bacterial lysis properties using
electron microscopy and that LL-37 is protected against the
action of proteolytic degradation, since in solution it forms
aggregates and it also forms a lipid bilayer (103, 104).
As the human AMP, LL-37 is toxic at high doses, synthetic
(mimetics) AMPs were developed incorporating a specific
sequence structure to develop synthetic anti-lipopolysaccharide
peptides (SALPs) with an improved ability to bind and neutralize
the lipid Amoiety of LPS in order to reduce toxicity and optimize
antimicrobial activity. Peptide 19-2.5 belongs to the new
synthetic AMPs and has been designed to strongly bind LPS
and causes the lipid A part of LPS to convert from a cubic
aggregate into an inactive multi-lamellar structure and has
efficacy in preclinical models of sepsis (105). There is good
evidence that Peptide19-2.5 attenuates the systemic
inflammation and organ injury/dysfunction associated with
sepsis by binding to and inactivating LPS (106). Peptide 19-2.5
attenuates septic cardiomyopathy and prevents the
downregulation of SERCA2, which plays a pivotal role in the
cardiac dysfunction associated with sepsis (106). This peptide
combined to several unrelated antibiotics neutralize the serum
levels of TNF-a to control endotoxemia induced by bacterial
infection in mice (107). Hence, Peptide 19-2.5 can act as an anti-
endotoxin, since this peptide can effectively kill both Gram-
negative and Gram-positive bacteria, as well as being able to
neutralize endotoxin by sequestering LPS (107). Therefore,
suggesting a combination therapy of AMPs with antibiotics
may be an effective treatment for endotoxemia. Thus, synthetic
AMPs, such as Peptide 19-2.5 could be a potential lead candidate
for the treatment of metabolic endotoxemia.POTENTIAL DIETARY INTERVENTIONS
Treatment of metabolic endotoxemia is vital due to the range of
chronic diseases related to endotoxemia. Diet-based interventions
targeting the gut microbiota could reduce circulating levels of
endotoxins, hence can prevent the development of chronic low-
grade inflammation associated with endotoxemia. Modifying
lifestyle including minimizing alcohol consumption, increasing
diet rich in macronutrients, and reducing saturated fat intake can
all have an impact on reducing metabolic endotoxemia, as well as
prebiotics and probiotics have shown to reduce the levels of
circulating endotoxins.
Consuming a large amount of alcohol can cause changes to
the gastrointestinal tract since the enzyme for oxidative
metabolism of alcohol is present in the intestinal mucosa andFrontiers in Immunology | www.frontiersin.org 11the liver becomes overwhelmed, leading to the (i) disruption of
the intestinal barrier integrity causing an increase in the
permeability hence, elevating endotoxin levels in the systemic
circulation, (ii) altering the intestinal microbiota resulting in the
production of LPS (108). A positive correlation was found
between the quantity of alcohol consumption and the serum
LPS levels (109). These high endotoxin levels are due to the
prevention of Kupffer cells effectively clearing these molecules
from the circulation (110). The main oxidative metabolite in
alcohol, acetaldehyde alters the structure of the intestinal barrier
by disrupting the epithelial tight junctions therefore causing an
increase in intestinal permeability (111). Alcohol feeding in mice
results in an increase in the liver injury marker, serum alanine
aminotransferase (ALT), triglycerides and steatosis. However,
this was not seen in TLR4-KO mice (112). This suggests the
importance of the activation of TLR4 receptors by LPS on
Kupffer cells in liver injury.
Micronutrients are important in altering the gut microbiota
and micronutrient deficiencies affect the composition of the gut
microbiota. A diet lacking one or all of the four micronutrients
investigated: vitamin A, zinc, iron, or folic acid disrupted the
composition of the gut microbiota, with vitamin A deficiency
having the largest effect on altering the composition resulting in
an increase in Bacteroides vulgatus (113). Zinc is important in
maintaining the structure and function of the membrane barrier,
hence depletion of zinc was found to affect the barrier integrity
and function and cause an upregulation of chemokines (114).
Vitamin D is also important as treatment found to increase the
levels of claudin-1, claudin-2, and ZO-1, however mice lacking
vitamin D receptor, showed severe disruption in the epithelial
junctions after 3 days following dextran sulphate sodium
treatment to induce colitis (115). Hence micronutrient
deficiencies lead to an increase in intestinal permeability and
ultimately metabolic endotoaemia.
Diets high in saturated fats contribute to metabolic
endotoxemia and unsaturated diets such as the Mediterranean
diet rich in fruits, vegetables, nuts, and whole grain reduce
metabolic endotoxemia (116). Oils rich in saturated fats
including the western diet: vegetable, palm, and canola oils cause
endotoxemia, compared to oils rich in n-3 polyunsaturated fatty
acids (PUFA) attenuate endotoxemia. Also, dietary cod liver and
fish oils attenuate the level of endotoxin concentration compared to
coconut oil (117). The structure of fat that is consumed leads to the
changes in composition, hence altering the extent of endotoxemia.
Food additives including sugar, surfactants, and sodium chloride,
which are applied in high concentrations to commonly consumed
foods, have been suggested to increase intestinal permeability (118,
119). A Drosophila model and a human cell co-culture model was
used to demonstrate the effect of additives on the function of the
gut barrier, showing an increase in intestinal permeability (119).
Metabolic endotoxemia has been implicated in gut dysbiosis,
hence probiotics have been investigated as a dietary strategy. The
gut microbiota is the product of the interaction between the hosts
genetics and environment factors such as diet which influences
bacterial population. Gut microbiota is an important determinant
of metabolic disorders such as obesity and T2DM, since westernJanuary 2021 | Volume 11 | Article 594150
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activation of proinflammatory mechanisms and disrupting the
intestinal barrier, hence leading to metabolic endotoxemia (120).
Therefore, manipulating the gut microbiota with probiotics could
be used as a potential intervention to manage metabolic diseases.
Probiotics are defined as live microorganisms and the main
members of this group include, Bifidobacteria and lactobacilli
(120, 121). Orally administered probiotics, microencapsulated
Bifidobacterum infantis in rats for 38 days showed a significant
increase in Bifidobacteria and reduced serum endotoxins (122).
HFD-fed mice received Bifidobacteria for 4 weeks, this resulted in
a reduction in weight gain and attenuated the increase in blood
glucose, triglycerides, and total cholesterol caused by a HFD (123).
Probiotics change the bacterial composition in the gut as they are
in competition for metabolites, antimicrobial proteins, and
nutrients. Prebiotics also modulates the gut microbiota and
increases bifidobacterial. The main known prebiotics are non-
digestible carbohydrates such as inulin and fructooligosaccharides
(FOS) (124). Studies have shown the beneficial effects of prebiotics
for reducing metabolic endotoxemia (125). A clinical study with
30 obese women receiving maltidextrin or insulin-type fructans
prebiotics daily for 3 months showed a significant increase in
Bifidobacterium with Bifidobacterium longum showing a
negative correlation with the levels of serum LPS (126).
Thus, dietary interventions could control the level of
metabolic endotoxemia.LIMITATIONS
LAL Assay
The LAL assay is commonly used to detect endotoxins, however,
there are several limitations of this assay when aiming to reliably
quantify LPS levels in the blood. Firstly, there are limitations in
collecting blood samples to measure LPS in animals, as the blood
would have to be taken from the portal vein, which is not a trivial
procedure. It is also essential to avoid the contamination of the
blood sample with LPS during sample collection. There is
evidence that heparinized blood collection tubes are frequently
contaminated with endotoxin and this may lead to a false
positive result (127). False positive results may also be
secondary to the presence of plasma lipids, as these increase
the sensitivity of LAL assay due to the direct activation of LAL in
samples in which either triglycerides or very low-density
lipoproteins concentrations are high. Thus, blood samples
taken from subjects with T2DM, which frequently have high
serum triglyceride levels, have a higher chance to deliver false
positive results (128). To overcome this limitation, LPS and
mannan can by extracted in the nonlipid phase (129). It should
be noted that the LAL assay is also not endotoxin specific, as the
assay can also be activated by b-glycans, peptidoglycan from
Gram-positive bacteria, simple polysaccharides and dithiols
(130, 131). False negative results are also possible for the
following reasons: The lipid A component of LPS associates
with the phospholipid shell of serum lipoproteins when entering
the blood stream and this may hinder the detection of LPS by theFrontiers in Immunology | www.frontiersin.org 12enzymes of the LAL assay (132). In addition, the half-life of LPS
is very short, as it is rapidly sequestered by LBP (133). To
overcome all of these limitations (which is challenging), one
could use several assays togethers with the LAL assay, such as the
LBP assay and the endotoxin activity assay (EAA) (134). Thus,
care should be taken when attributing any pathology associated
with a positive LAL test result to the presence of LPS (cause-
effect-relationship). Further studies are necessary to clarify the
role of LPS in the pathophysiology of diseases associated with
metainflammation. Another limitation of the LAL assay is
suggested since the measurements of serum levels of LPS in
healthy individuals have shown to differ in different studies
ranging from 0.04 to 0.36 EU/ml (133). Also, the sample
preparation method used changes the levels, when samples are
treated with perchloric acid or Tween 80 the levels are higher
compared to heating and dilution (133).
Interventions Using AMPs
The gut microbiota confers health benefits to the host by aiding
both the protection of the gut and nutrient absorption (135).
Thus, the non-specific killing of bacteria in the gut by AMPs may
have detrimental effects on gut health. However, AMPs kill
bacteria at non-toxic concentrations (136). AMPs are
becoming a focus as new treatments, as the rising rate of
multi-resistant bacteria, poses a challenge for the treatment of
patients with severe infections, due to either misuse or excessive
use of antibiotics. There is also the added problem that
antibiotics kill bacteria; however, they also cause the release of
bacterial wall fragments including lipopolysaccharide (LPS) or
lipoprotein (LP). This leads to the initiation of the pro-
inflammatory cascade and this can potentially cause harm (85).
Therefore, there is a need for new treatments that are both
effective and safe. The World Health Organization has stated
antibiotic resistance as one of the biggest threats to human health
(137). By 2050, it has been estimated that 10 million people
worldwide will die every year from drug-resistant bacteria (138).
AMPs could potentially be used as new treatments, as they
kill bacteria, fungi, and viruses. The antimicrobial properties of
AMPs are produced in many ways, as they have multifunctional
properties, and this makes them less likely to become resistant to
microorganisms. A combination therapy of both antimicrobial
peptides and antibiotics may be a promising approach, which
would allow a reduction of the doses of antibiotics, therefore
lowering the potential side-effects, while the combination
therapy may also prevent the development of bacterial
resistance. However, any long-term treatment with AMPs may
also trigger the development of resistance and the rate is
determined by several factors, such as the mutation supply rate
(139). AMPs can develop mechanisms to resist the action of
antibiotic in their natural environment of bacteria in intrinsic
resistance and acquired resistance is due to mutated genes that
allow bacteria to grow when AMPs are present (136). Resistance
can also occur due to changes in the net surface charge of the
bacteria, hence reducing their attraction to AMPs (81). Other
mechanisms of AMP resistance includes the proteolytic
degradation of AMPs by extracellular proteases of Gram-January 2021 | Volume 11 | Article 594150
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peptidoglycans of Gram-negative bacteria (140).
Antibody Therapy
Antibody therapies as a potential intervention for metabolic
endotoxemia has limitations, since there is diversity in O-
polysaccharide targets that are expressed by different Gram-
negative bacteria in the gut. Antibody specificities are directed
mainly against the O-polysaccharide of LPS, hence are specific
for one particular O-antigen. Therefore, this makes it not
possible to use one anti-LPS antibody to target one bacterium.CONCLUSION
The concept of metabolic endotoxemia is still controversial, as
most of the evidence in support of a role of endotoxemia as the
key driver of meta-inflammation relies on data generated with
the LAL assay, which has significant limitations. Findings
indicating that TLR-4 knockout mice have less pathology when
challenged with a HFD would support the notion that metabolicFrontiers in Immunology | www.frontiersin.org 13endotoxemia plays a key role in the pathophysiology. Similarly,
the finding that ApoE-knockout mice deficient in TLR-4 have
less atherosclerotic burden also supports the notion of a role of
metabolic endotoxemia in atherosclerosis. The question of a true
cause-effect relationship of LPS in metabolic disorders will have
to be addressed by pharmacological or dietary interventions that
specifically target metabolic endotoxemia and this remains a
significant challenge.AUTHOR CONTRIBUTIONS
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